Compare AbCellera Biologics Inc (ABCL) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs FuelCell Energy Inc — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while FuelCell Energy Inc trades at $23.04 (market cap $1.76B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | FCEL | |
|---|---|---|
Market Cap | $2.35B | $1.76B |
Sector | Health | Industrials |
52-Week High | $8.12 | $36.01 |
52-Week Low | $2.78 | $3.92 |
Enterprise Value | $1.99B | $1.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FCEL trades at $25.96, down 7.65% amid a $200 million stock offering announcement, yet maintains a bullish technical signal with support near $25. Revenue grew to $158.16M in 2025, but profitability remains challenged with a net income margin of -132.41%. Recent news highlights a 5 GW proposal pipeline, with 90% tied to data center power demand, and a $49 million EXIM financing boost for global expansion.
The outlook is speculative; growth potential from AI-driven data center deals and clean energy exports is offset by persistent losses, negative cash flow from operations, and dilution risk from equity offerings. Analyst consensus is mixed with a $20.13 price target, suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
